Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Liquid Molecular Testing Panel in the Community Setting ("DINOSAur II")

Glendale Adventist Medical Center d/b/a Adventist Health Glendale

Status: Enrolling

Conditions: Stage III Solid Tumors; Stage IV Solid Tumors

Treatments: Diagnostic Test: Comprehensive liquid molecular panel test; Other: EORTC QLQ-30

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT05703243

DINOSAur II

Details and patient eligibility

About

To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive l i q u i d molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.

Enrollment: 572 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who have given informed consent in accordance with the methods and procedures of this study
• Diagnosis of cancer (stage 3 and stage 4; solid tumors only) requiring medical care
• Patients who have not received treatment related to his/her cancer
• Patients who are willing to sign a release of medical records to the research team
• Male and female patients ≥18 years of age
• Patients under oncology care
• Sufficient clinical status for collection of blood sample within usual care

Exclusion criteria

• Patients considered minors in the jurisdiction where the protocol is conducted
• Patients who are prisoners and pregnant women
• Patients who cannot provide consent and did not sign a power of attorney

Trial design

572 participants in 2 patient groups

Active

Description:

Newly diagnosed cancer patients.

Treatment:

Other: EORTC QLQ-30

Diagnostic Test: Comprehensive liquid molecular panel test

Control

Description:

Historically diagnosed cancer patients.